Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.07 USD | +0.41% | +26.26% | +14.56% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.56% | 8.44B | B- | ||
-14.44% | 77.05B | B+ | ||
+25.88% | 3.73B | B- | ||
+0.42% | 3.33B | B- | ||
+17.06% | 1.69B | - | ||
-8.82% | 1.52B | B | ||
-22.51% | 1.3B | C- | ||
-2.64% | 1.27B | - | ||
-10.11% | 1.18B | - | ||
+4.27% | 1.09B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ELAN Stock
- Ratings Elanco Animal Health Incorporated